|
市場調査レポート
商品コード
1306527
血管内超音波カテーテルの世界市場:規模、シェア、COVID-19の影響分析(2023年~2029年)、地域別セグメント:MedCoreIntravascular Ultrasound Catheter Market Size, Share & COVID19 Impact Analysis | Global | 2023-2029 | MedCore | Segmented by: Global Regions |
||||||
適宜更新あり
|
血管内超音波カテーテルの世界市場:規模、シェア、COVID-19の影響分析(2023年~2029年)、地域別セグメント:MedCore |
出版日: 2023年06月05日
発行: iData Research Inc.
ページ情報: 英文 27 Pages
納期: 即日から翌営業日
|
世界の血管内超音波(IVUS)カテーテルの市場規模は、2022年に2億5,500万米ドルに達しました。同市場は、予測期間中に8.4%のCAGRで拡大し、2029年には4億5,100万米ドル近くに達すると予測されています。
当レポートでは、世界の血管内超音波カテーテル市場について調査し、市場の概要とともに、セグメント別、地域別動向、競合情勢などを提供しています。
The global market for IVUS catheters reached a valuation of over $255 million in 2022 and is projected to grow at a CAGR of 8.4% during the forecast period, reaching nearly $451 million.
IVUS catheters are utilized in conjunction with various minimally invasive cardiovascular devices. They are predominantly employed in angioplasty procedures, either before, during, or after the intervention. It is important to note that these procedures necessitate the availability of an IVUS console within catheterization laboratories (cath labs).
The adoption of intravascular imaging technologies, including IVUS and OCT, is witnessing a growing trend, with both technologies competing for popularity. As alternative options to angiography, this competition is projected to have a limiting effect on market growth. However, as physician training and clinical awareness regarding IVUS continue to improve, there is an increasing penetration of procedures utilizing this technology. This standardized utilization, along with the anticipated rise in market value, is expected to be driven by the growing acceptance of IVUS worldwide, although North America and Asia Pacific currently lead in device adoption. Other regions across the globe are gradually embracing this technology as well.
In 2022, the global IVUS catheter market was primarily dominated by two key players, namely Philips and Boston Scientific.
Philips emerged as the leading competitor in the market, offering the Eagle Eye Platinum™ and Revolution™ IVUS catheter product lines that are compatible with their Core™ and Core Mobile™ IVUS console product lines. These consoles provide options for fractional flow reserve (FFR), instantaneous wave-free ratio (IFR), and IVUS modalities in a single platform. Philips is expected to leverage its strong presence in the coronary balloon catheter market to maintain its leading position in the IVUS market.
Boston Scientific, on the other hand, secured the second-leading position in the global IVUS catheter market in 2022. The company introduced its OptiCross™ IVUS device, which received clearance from the FDA, CE Mark, and approval from Japan PMDA, allowing its availability in the U.S., Europe, and Japan, respectively. The OptiCross™ IVUS device was designed with input from physicians worldwide, aiming to improve functionality during complex cases. Boston Scientific's effective coordination of sales between its drug-eluting stents and IVUS catheters further strengthens its competitive position in the market.
Throughout this research series, iData Research has extensively covered several regions. The regions covered in our research include: